We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Placebo Snafu Forces Cytokinetics to Amend Phase II Trial of ALS Drug
Placebo Snafu Forces Cytokinetics to Amend Phase II Trial of ALS Drug
July 19, 2013
California-based Cytokinetics says a programming error in its electronic data capture system led 58 patients with amyotrophic lateral sclerosis (ALS) in a Phase IIb trial on its investigational drug tirasemtiv to be switched to the placebo arm.